RTTR Ritter Pharmaceuticals Inc.

0.35
-0.00  -1%
Previous Close 0.35
Open 0.36
Price To book 17.55
Market Cap 17376789
Shares 49,506,521
Volume 91,282
Short Ratio 0.36
Av. Daily Volume 1,280,367

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2/3 top-line data released March 28, 2017. Primary endpoint met. End of Phase 2 meeting with FDA planned by the end of 2017 with Phase 3 trial to potentially commence 1H 2018.
RP-G28
Lactose intolerance

Latest News

  1. Zacks.com featured highlights: Fortuna Silver Mines, Ritter Pharmaceuticals , Organovo Holdings, Western Digital and Willdan Group
  2. Ritter Pharmaceuticals Presents at the 5th Microbiome R&D Business Collaboration Forum / 2nd Annual Probiotic Congress
  3. Ritter Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
  4. Ritter Pharmaceuticals, Inc. Raises $23 Million to Fund Initiation of Its Phase 3 Clinical Program in Lactose Intolerance
  5. Ritter Pharmaceuticals, Inc. Prices $23,000,000 Public Offering
  6. Corporate News Blog - Ritter Pharma Announces Phase-3 Plans After End of Phase-2 Meeting with the FDA on RP-G28 for Lactose Intolerance
  7. Today's Research Reports on Stocks to Watch: Amicus Therapeutics Inc. and Ritter Pharmaceuticals Inc.
  8. Ritter Pharmaceuticals Announces Phase 3 Plans after its End of Phase 2 Meeting with FDA on RP-G28 for Lactose Intolerance
  9. Zacks.com featured highlights: Post Holdings, Duluth Holdings, Ritter Pharmaceuticals, Koppers Holdings and Silicon Laboratories
  10. Ritter Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
  11. Ritter Pharmaceuticals Reports Further Analysis from its Phase 2b/3 Trial Results Demonstrating Significant Reductions in Lactose Intolerance Symptoms
  12. Ritter Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Updates
  13. Ritter Pharmaceuticals, Inc. Announces End of Phase 2 Meeting with the FDA and Initiates Phase 3 Program Development Activities
  14. Ritter Pharmaceuticals Announces Lactose Intolerance Treatment, RP-G28, Demonstrated Efficacy and Clinically Meaningful Benefit in Phase 2b/3 Clinical Trial
  15. Ritter Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update
  16. Ritter Pharmaceuticals Announces Collaboration with University of British Columbia to Explore Development of Microbiome Therapeutics in Environmental Enteropathy
  17. Ritter Pharmaceuticals to Ring Today's Nasdaq Stock Market Closing Bell to Kick-off Lactose Intolerance Awareness Month
  18. Ritter Pharmaceuticals Announces Collaboration with University of Nebraska to Explore Development of Microbiome Therapeutics in Metabolic Syndrome